# Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

> **NCT04367441** · PHASE1 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 62 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** 608
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04367441
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-25
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-10-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04367441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04367441, "Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04367441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*